AsianScientist (Jul. 18, 2012) – A*STAR Chief Scientist, Professor Sir David Lane is the recipient of the 2012 Cancer Research UK Lifetime Achievement in Cancer Research Prize.
The prize recognizes the pioneering research of Lane that led to the discovery of p53, often called the ‘guardian of the genome.’
Lane was knighted for his services to cancer research in 2000, and he served as the charity’s first chief scientist between 2007 and 2010.
Since the discovery of the p53 protein in 1979, he has dedicated his career to understanding how it protects against cancer. His recent work has focused on controlling p53 and this has identified several promising targets for developing new cancer drugs.
“I’m delighted to receive this award, which would not have been possible without the support of my colleagues and Cancer Research UK,” said Lane, who now runs the p53 Lab under A*STAR.
“It is an exciting time to be in the field of p53 research and we continue to tackle the more challenging aspects of p53 research here at A*STAR.”
On Friday last week, Lane officiated the opening of a new Tokyo-based Chugai Pharmaceutical Co., Ltd. venture in Singapore as the chairman of the board.
The Singapore-based Chugai Pharmabody Research Pte. Ltd. (CPR), located at A*STAR’s Biopolis R&D hub, will screen antibody drug candidates for therapeutic potential using Chugai’s proprietary antibody engineering technologies and employ approximately 60 researchers.
As the chief scientist of the Agency for Science, Technology and Research (A*STAR), Singapore’s lead research agency, Lane is involved in the scientific direction of 14 biomedical, physical, and engineering research institutes, and six consortia and centers.
Professor Lane will be presented with the award at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool on November 4, where he will also give a plenary lecture.
——
Source: A*STAR.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
